Rag2/IL2rg/Flt3-KO(BALB/c)
Nomenclature
BALB/cJSmo-Rag2em1IL2rgem1Flt3em1Smoc
Cat. NO.
NM-KO-234080
Strain State
Embryo Cryopreservation
Gene Summary
Gene Symbol
Flt3
Model Description
Validation Data
Fig.1 Percentage of T, B, NK cell subsets in spleen (n=5).
Fig.2 Percentage of T, B, NK cell subsets in PB (n=5).
Fig.3 Detection of mouse Flt3 Ligand expression in serum by ELISA (n=5).
Abbr. HO, homozygous; WT, wild type; N.D. not detected.
Fig.4 Body weight growth curve of M-NSG and Rag2/IL2rg/Flt3-KO (BALB/c) mice post human HSC inoculation.
Human CD34+ HSCs (1E5) were intravenously injected into homozygous Rag2/IL2rg/Flt3-KO (BALB/c) and M-NSG mice (n=8-10, female, 3-4 weeks). 
Fig.5 Humanized immune reconstitution levels in M-NSG and Rag2/IL2rg/Flt3-KO (BALB/c) mice engrafted with human HSC.
Human CD34+ HSCs (1E5) were intravenously injected into homozygous Rag2/IL2rg/Flt3-KO (BALB/c) and M-NSG mice (n=8-10, female, 3-4 weeks). All mice received 1.0 Gy irradiation prior to cell inoculation. Peripheral blood were analyzed by flow cytometry at indicated time points post inoculation. No significant differences were observed between the two mouse strains across the examined human immune cell subsets.
Fig.6 Percentages of pDCs, cDCs, and monocytes within human CD45 population were determined in the spleen of Rag2/IL2rg/Flt3-KO (BALB/c) mice by FACS.
After 16 weeks of human immune reconstitution, mice received intraperitoneal injections of hFlt3L‑Fc (5 μg per mouse) three times per week for 2 weeks. One week after the final injection, mice were euthanized and spleens were harvested for immune cell analysis. The results demonstrated that hFlt3L‑Fc treatment significantly increased the percentages of plasmacytoid dendritic cells (pDCs) and conventional dendritic cells (cDCs), while moderately elevating the proportion of monocytes (n=4–5 females per group) (Mean±SEM, Unpaired t-test, ***P< 0.001).
You may also like
Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreWorkshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
